Dr. Dario Rusciano (born in 1955) completed his PhD in Cell and Molecular Biology at Pisa University (Italy) in 1979. He was involved as post-doc and project leader in basic research on the organ specificity of cancer metastasis at the Sclavo pharmaceutical company of Siena (Italy) from 1982 to 1989, and then at the Friedrich Miescher Institute of Basel (Switzerland) until the year 2000. He then shifted his interests towards translational research in ophthalmology, working as lab leader for the next 7 years in SIFI, a pharmaceutical company based in Sicily (Italy), and then at Sooft, another pharmaceutical company now owned by Fidia Pharmaceuticals (Abano Terme, Italy), where he was appointed research director for ophthalmology. He retired in 2022 and presently works as a scientific consultant for different clients. Most recently, he resumed his interest in oncology, updating his last project in precision oncology and personalized tumor therapies by using essentially three levels of analysis. He has authored over 100 papers published in international refereed journals, and one book on the experimental approaches in cancer metastasis (Elsevier, 2000: https://www.elsevier.com/books/cancer-metastasis-experimental-approaches/rusciano/978-0-444-82372-4). He is present on Research Gate (https://www.researchgate.net/search/publication?q=dario+rusciano) and LinkedIn (Feed | LinkedIn). Orcid access number: 0009-0009-4707-7949.